Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Similar documents
Out-Patient Billing CPT Codes

August 17, Dear Valued Client:

NeoTYPE Cancer Profiles

NeoTYPE Cancer Profiles

Pediatric Oncology & Pathology Services

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

The Center for PERSONALIZED DIAGNOSTICS

molecular oncology services

Time Matters. Results Count! Company Overview Presentation. August Improving Patient Care through exceptional cancer genetic testing services!

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Prior Authorization Required: Additional Information:

West Midlands Regional Genetics Laboratory

Molecular Advances in Hematopathology

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare

ADRL Advanced Diagnostics Research Laboratory

Your single-source laboratory solution. FISH Probe Library

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Initial Diagnostic Workup of Acute Leukemia

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Laboratory Service Report

Please Silence Your Cell Phones. Thank You

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Genetic Testing for Somatic Tumor Markers

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Laboratory Service Report

Precision Medicine and Molecular Testing.

Click to edit Master /tle style

SUPPLEMENTARY INFORMATION

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology

Diagnostic Molecular Pathology of Myeloid Neoplasms

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

MOLECULAR SERVICES. mlabs.umich.edu

Update on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Molecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Test Name Results Units Bio. Ref. Interval. Positive

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Current Techniques in Molecular Biology Friedel Nollet, Ph.D.

Molecular Diagnostics Centre

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

The Next Generation of Hereditary Cancer Testing

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university

[COMPREHENSIVE GENETIC ASSAY PANEL ON

Accel-Amplicon Panels

School of Pathology and Laboratory Medicine: Current and New Research Interests

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!

HEMATOPATHOLOGY SERVICES

Test Name Results Units Bio. Ref. Interval. Positive

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Management of Myelodysplastic Syndromes

Objectives and Financial Disclosure

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Transform genomic data into real-life results

Genetic Testing Oncology

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations

Genomic Medicine: What every pathologist needs to know

Session 4: Summary and Conclusions

Molecular Genetic Testing for the Diagnosis of Haematological Malignancies

Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia

GENETICS OF HEMATOLOGICAL MALIGNANCIES

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Lynch Syndrome. Angie Strang, PGY2

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome

Cleveland Clinic Laboratories. Anatomic Pathology

Published Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.

MEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17

CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA

Recommended Timing for Transplant Consultation

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Oxford BRC Haemato-Molecular Diagnostic Service

Next generation sequencing analysis - A UK perspective. Nicholas Lea

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

CHALLENGING CASES PRESENTATION

Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017

Transcription:

Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine

Molecular testing has become the primary tool for precision medicine. NeoGenomics is a full-service cancer diagnostic laboratory committed to helping the cancer community incorporate informative, effective, and innovative tests into the care of their patients. With over 155 molecular assays in-house, we provide one of the largest oncology-focused molecular test menus available along with top-quality consultation and laboratory services in cytogenetics, FISH, flow cytometry, and IHC. NeoGenomics has developed a unique expertise in analysis and reporting of cancer biomarkers. By having one of the fastest development cycles in the industry, we are also responsive to opportunities to improve service and patient care. We rapidly bring our clients state-of-the-art tests for newly reported, significant genetic indicators for disease diagnosis and classification, assessing prognosis, and selecting therapy. Our oncology and pathology clients always have the flexibility to customize their orders to their patient s specific needs. Highlights of Our Molecular Program Include: One of the most comprehensive oncology-focused menus of single-gene and multi-parameter tumor profiles available Full range of molecular diagnostic technologies including next-gen sequencing, quantitative PCR, gold-standard Sanger sequencing, fragment analysis, and SNP microarray Extensive cell-free DNA/RNA liquid biopsy testing capabilities useful for diagnostic screening, monitoring and detecting minimal residual disease All complementary testing methods including morphology, cytogenetics, FISH, flow cytometry, and IHC are available in-house, which maximizes yield from small specimens and minimizes TAT Growing hereditary cancer testing menu using leading-edge platforms Pharma Services supporting academic institutions, pharmaceutical companies, and the biotechnology industry Testing enhancements to improve detection of low-level abnormalities in select assays through plasma analysis and high-sensitivity sequencing Molecular Testing Capabilities Somatic Germline Early Detection/ Prediction 2 NeoGenomics Laboratories

Solid Tumor Tests All Tumors Microsatellite Instability Analysis (MSI) NeoARRAY SNP/Cytogenetic Profile NeoLAB Solid Tumor Monitor NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Precision Profile for Solid Tumors Tumor Mutation Burden Universal Expression/Fusion Profile Brain ATRX viii Analysis IDH1/IDH2 MGMT Promoter Methylation NeoTYPE Brain Tumor Profile TERT Promoter Breast NeoTYPE Breast Tumor Profile Cervical RAF NeoTYPE Cervical Tumor Profile NOTCH1 Colorectal Exon 4 Microsatellite Instability Analysis (MSI) MLH1 Promoter Methylation NeoTYPE Colorectal Tumor Profile NeoTYPE GI Predictive Profile NOTCH1 Exon 4 RAS/RAF Panel Esophageal NeoTYPE Esophageal Tumor Profile NeoTYPE GI Predictive Profile Gastric NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile GIST NeoTYPE GIST Profile Lung ALK MET MET Exon 14 Deletion Analysis NeoLAB T790M - NeoTYPE Lung Tumor Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile Oncomine Dx Target Test Melanoma NeoARRAY SNP/Cytogenetic Profile NeoTYPE Melanoma Profile TERT Promoter Ovarian NeoTYPE Ovarian Tumor Profile TP53 Soft Tissue NeoTYPE Liposarcoma Fusion Profile NeoTYPE Soft Tissue Tumor Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile Prostate Androgen Receptor Mutation Analysis HSD3B1 Genotyping NeoLAB Prostate - Thyroid HRAS NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Thyroid Fusion Profile TERT Promoter Other Tumors HPV DNA Tissue Testing NeoTYPE Head & Neck Tumor Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Pancreas Tumor Profile NeoGenomics Laboratories 3

Hematologic Diseases Leukemias AML ASXL1 CEBPA DNMT3A ETV6-RUNX1 t(12;21) FLT3 IDH1 IDH2 Inv(16) CBFB-MYH11 NeoLAB AML Profile - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB Inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(16;17) - Liquid Biopsy NeoTYPE AML Favorable Risk Profile NeoTYPE AML Prognostic Profile NPM1 NPM1 MRD Analysis PML-RARA t(15;17) RUNX1 RUNX1-RUNX1T1 t(8;21) TP53 APL PML-RARA t(15;17) ALL ABL1 Kinase Domain Mutation B-Cell Gene Rearrangement BCR-ABL1 t(9;22) ETV6-RUNX1 t(12;21) IgH Clonality/MRD by NGS T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TPMT Genotyping CLL BTK Inhibitor Acquired Resistance Panel BTK IgVH NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoTYPE CLL Prognostic Profile NOTCH1 PLC-Gamma-2 SF3B1 JMML NeoLAB Mutation Analysis - NeoTYPE JMML Profile PTPN11 Other Leukemias Hairy Cell: LGLL: STAT3, T-Cell Lymphomas B-Cell Gene Rearrangement BCL1 t(11;14) BCL2 t(14;18) BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel EZH2 IgH Clonality/MRD by NGS MYD88 NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE Lymphoma Profile RHOA Mutation Analysis T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TET2 Myelodysplastic Syndromes ASXL1 ETV6 EZH2 NeoARRAY SNP/Cytogenetic Profile NeoLAB Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoTYPE MDS/CMML Profile PPM1D RUNX1 SF3B1 TET2 TP53 Myeloproliferative Neoplasms BCR-ABL1 t(9;22) BCR-ABL p230 CALR JAK2 Exon 12-14 JAK2 V617F MPL MPN Extended Reflex Panel MPN Standard Reflex Panel NeoLAB Mutation Analysis - NeoTYPE MPN Profile CML ABL1 BCR-ABL1 t(9;22) CSF3R for acml Plasma Cell Myeloma B-Cell Gene Rearrangement Transplant Chimerism/DNA Fingerprinting 4 NeoGenomics Laboratories

Hereditary Cancer Tests BRCA1 Mutation & Del/Dup Analysis BRCA1/2 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis T790M Germline Mutation Analysis Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer HOXB13 Genotyping Inherited Bone Marrow Failure Panel Lynch Syndrome NeoLAB Tests NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB Prostate - NeoLAB RUNX1-RUNX1T1 (AML-ETO) - NeoLAB Solid Tumor Monitor - NeoGenomics Laboratories 5

Test Menu Single Gene Tests ABL1 Kinase Domain ALK Androgen Receptor ASXL1 ATRX B-Cell Gene Rearrangement BCL1 Translocation, t(11;14) BCL2 Translocation, t(14;18) BCR-ABL1 Non-Standard p230 BCR-ABL1 Standard p210, p190 BRCA1 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis BTK CALR CARD11 CBL CD79B CEBPA Chimerism/DNA Fingerprinting CSF3R CXCR4 DNMT3A T790M Germline Mutation Analysis viii Analysis EPCAM Mutation & Del/Dup Analysis ETV6 ETV6-RUNX1 Translocation, t(12;21) EZH2 FLT3 GNAS HOXB13 Genotyping HPV DNA Tissue Testing HRAS HSD3B1 Genotyping IDH1 & IDH2 IgH Clonality/MRD by NGS IgVH Inv(16), CBFB-MYH11 Translocation JAK2 Exon 12-14 JAK2 V617F Exon 4 MET (c-met) MET Exon 14 Deletion Analysis MGMT Promoter Methylation Microsatellite Instability MLH1 Mutation & Del/Dup Analysis MLH1 Promoter Methylation MPL MYD88 MSH2 Mutation & Del/Dup Analysis MSH6 Mutation & Del/Dup Analysis NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - NOTCH1 NPM1 Exon 4 PML-RARA Translocation, t(15;17) PMS2 Mutation & Del/Dup Analysis PTPN11 PLC-Gamma-2 PMS2 Mutation & Del/Dup Analysis RHOA RUNX1 RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) SETBP1 SF3B1 SRSF2 STAT3 T-Cell Gamma Gene Rearrangement T-Cell Beta Gene Rearrangement TERT Promoter TET2 TP53 TPMT Genotyping U2AF1 UGT1A1 Genotyping VHL WT1 ZRSR2 6 NeoGenomics Laboratories

Panels and Profiles AML Reflex Panel BRCA1/2 Mutation & Del/Dup Analysis BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer Inherited Bone Marrow Failure Panel Lynch Syndrome MPN Extended Reflex Panel MPN Standard Reflex Panel NeoARRAY SNP/Cytogenetic Profile NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB Prostate - Liquid to Biopsy NeoLAB Solid Tumor Monitor - NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE AML Favorable-Risk Profile NeoTYPE AML Prognostic Profile NeoTYPE Brain Tumor Profile NeoTYPE Breast Tumor Profile NeoTYPE Cervical Tumor Profile NeoTYPE CLL Prognostic Profile NeoTYPE Colorectal Tumor Profile NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Endometrial Tumor Profile NeoTYPE Esophageal Tumor Profile NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile NeoTYPE GIST Profile NeoTYPE Head & Neck Tumor Profile NeoTYPE JMML Profile NeoTYPE Liposarcoma Fusion Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Lung Tumor Profile NeoTYPE Lymphoma Profile NeoTYPE MDS/CMML Profile NeoTYPE Melanoma Profile NeoTYPE MPN Profile NeoTYPE Myeloid Disorders Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Ovarian Tumor Profile NeoTYPE Pancreas Tumor Profile NeoTYPE Precision Profile for Solid Tumors NeoTYPE Soft Tissue Tumor Profile NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile NGS Thyroid Fusion Profile RAS/RAF Panel Tumor Mutation Burden Universal Fusion/Expression Profile Specimen and Ordering Information Specimen Requirements NeoGenomics molecular testing is routinely performed on blood, bone marrow aspirate, fixed cytogenetic pellets, fresh tissue, and formalin-fixed paraffin-embedded tissue of all types. Acceptable specimen types vary by test, so please see our website for requirements for the test of interest. Please inquire if you have an alternative specimen type as we can often accommodate these. Ordering Tests in panels or profiles may be ordered separately or in custom combinations. The most commonlyordered tests are shown, but for many diseases, more testing that encompasses emerging research and clinical trial opportunities is available. For an extended list of tests correlated with each tumor, please search by disease state on the NeoGenomics website. NeoGenomics Laboratories 7

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information. 12701 Commonwealth Dr., Suite 9 Fort Myers, FL 33913 Phone: 866.776.5907/ Fax: 239.690.4237 neogenomics.com 2018 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev. 041718